Abstract
Nuclear medicine imaging for prostate cancer has advanced significantly over the past decade. A survey is presented in this review. PSMA-PET/CT is a new highly accurate method that has been introduced, but bone scans and bone-PET continue to be widely applied. PSMA-PET/CT still lacks sufficient patient outcome data to be recommended for treatment allocation when used for primary staging. However, the literature and clinical guidelines support its use at the stage of biochemical recurrence. In Denmark, the use of nuclear medicine examinations for prostate cancer aligns with clinical guideline recommendations.
Bidragets oversatte titel | Indications for nuclear medicine imaging in prostate cancer |
---|---|
Originalsprog | Dansk |
Artikelnummer | V01240036 |
Tidsskrift | Ugeskrift for Læger |
Vol/bind | 186 |
Antal sider | 7 |
ISSN | 0041-5782 |
DOI | |
Status | Udgivet - 12 aug. 2024 |
Bibliografisk note
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.Emneord
- Humans
- Male
- Prostatic Neoplasms/diagnostic imaging
- Positron Emission Tomography Computed Tomography
- Bone Neoplasms/diagnostic imaging
- Radiopharmaceuticals
- Nuclear Medicine
- Neoplasm Staging
- Neoplasm Recurrence, Local/diagnostic imaging
- Practice Guidelines as Topic